Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cullinan Therapeutics, Inc. CGEM NASDAQ

NASDAQ Global Select • Healthcare • Medical - Pharmaceuticals • US • USD

SharesGrow Score
60/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$30.43
+112.1%

Cullinan Therapeutics, Inc. (CGEM) is a Medical - Pharmaceuticals company in the Healthcare sector, currently trading at $14.35. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is CGEM = $30 (+112.1% upside).

Valuation: CGEM trades at a trailing Price-to-Earnings (P/E) of -4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.65.

Net income is $220M (loss), growing at -92.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $3M against $409M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 10.25 (strong liquidity). Debt-to-assets is 0.6%. Total assets: $448M.

Analyst outlook: 8 / 8 analysts rate CGEM as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 83/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 100/100 (Pass), Moat 34/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$30.43
▲ 112.06% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Cullinan Therapeutics, Inc., the average price target is $30.43, with a high forecast of $38.00, and a low forecast of $26.00.
Highest Price Target
$38.00
Average Price Target
$30.43
Lowest Price Target
$26.00

CGEM SharesGrow Score Overview

60/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 83/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 34/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CGEM

✓
VALUE Pass
83/100
CGEM trades at a trailing Price-to-Earnings (P/E) of -4 (S&P 500 average ~25). Forward PEG 0.65 — Peter Lynch undervalued (≤1.0). Trailing PEG 2.96. Analyst consensus target is $30, implying +109.1% from the current price $14. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
CGEM: +0%/yr revenue is, -92.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
CGEM: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet CGEM: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 10.25 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
34/100
CGEM: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 34/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 8 / 8 analysts rate CGEM as buy (100%). Analyst consensus target is $30 (+109.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range5.68-16.74
Volume872.71K
Avg Volume (30D)799.09K
Market Cap$868.55M
Beta (1Y)-0.11
Share Statistics
EPS (TTM)-3.72
Shares Outstanding$59.05M
IPO Date2021-01-08
Employees111
CEONadim Ahmed
Financial Highlights & Ratios
Gross Profit$-311K
EBITDA$-241.65M
Net Income$-219.88M
Operating Income$-241.65M
Total Cash$377.9M
Total Debt$2.68M
Net Debt$-85.65M
Total Assets$448.37M
Price / Earnings (P/E)-3.9
Analyst Forecast
1Y Price Target$30.00
Target High$38.00
Target Low$26.00
Upside+109.1%
Rating ConsensusBuy
Analysts Covering8
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS2300311063

Price Chart

Track all markets on TradingView
CGEM
Cullinan Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Medical - Pharmaceuticals
5.68 52WK RANGE 16.74

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 OLMA
OLMA
Olema Pharmaceuticals, Inc.
$16.30
+2.32%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 SANA
SANA
Sana Biotechnology, Inc.
$3.48
+8.41%
 LIFE
LIFE
aTyr Pharma, Inc.
$14.69
+2.23%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message